(Q58414406)

English

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

No description defined

In more languages

Statements

scholarly article

0 references

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) (English)

0 references

cancer research

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Aristoteles A N Giagounidis

4

object named as

Aristoteles Giagounidis

0 references

author name string

Oliver G. Ottmann

1

0 references

Barbara Wassmann

2

0 references

Heike Pfeifer

3

0 references

Matthias Stelljes

5

0 references

Ulrich Dührsen

6

0 references

Marc Schmalzing

7

0 references

Lydia Wunderle

8

0 references

Anja Binckebanck

9

0 references

Dieter Hoelzer

10

0 references

language of work or name

0 references

publication date

2007

0 references

0 references

109

0 references

10

0 references

2068-2076

0 references

Acute lymphoblastic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute lymphocytic leukemia (ALL) in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute lymphoblastic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of acute lymphoblastic leukemia in older patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in elderly acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Philadelphia chromosome-positive acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22631

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22631

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58414406&oldid=1949092627"